413 related articles for article (PubMed ID: 25683226)
1. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
2. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy.
Carlberg VM; Davies OMT; Brandling-Bennett HA; Leary SES; Huang JT; Coughlin CC; Gupta D
Pediatr Dermatol; 2021 Jan; 38(1):18-30. PubMed ID: 33378085
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
5. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
6. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
[TBL] [Abstract][Full Text] [Related]
7. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.
Belum VR; Cercek A; Sanz-Motilva V; Lacouture ME
Curr Treat Options Oncol; 2013 Sep; 14(3):389-404. PubMed ID: 23996476
[TBL] [Abstract][Full Text] [Related]
9. Non-rash dermatologic adverse events related to targeted therapies.
Bryce J; Boers-Doets CB
Semin Oncol Nurs; 2014 Aug; 30(3):155-68. PubMed ID: 25085027
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
11. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
12. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
Ensslin CJ; Rosen AC; Wu S; Lacouture ME
J Am Acad Dermatol; 2013 Nov; 69(5):708-720. PubMed ID: 23981682
[TBL] [Abstract][Full Text] [Related]
13. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
17. Alopecia in patients treated with molecularly targeted anticancer therapies.
Belum VR; Marulanda K; Ensslin C; Gorcey L; Parikh T; Wu S; Busam KJ; Gerber PA; Lacouture ME
Ann Oncol; 2015 Dec; 26(12):2496-502. PubMed ID: 26387145
[TBL] [Abstract][Full Text] [Related]
18. Nasal vestibulitis due to targeted therapies in cancer patients.
Ruiz JN; Belum VR; Boers-Doets CB; Kamboj M; Babady NE; Tang YW; Valdez TA; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2391-8. PubMed ID: 25876156
[TBL] [Abstract][Full Text] [Related]
19. Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME; Boerner SA; Lorusso PM
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S36-42. PubMed ID: 17239289
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD; Kwong BY
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
